So far, two JAK inhibitors have approval for treating UC in adults. The Food and Drug Administration (FDA) approved tofacitinib (Xeljanz) in 2018 and upadacitinib (RINVOQ) in 2022. These JAK ...

After the review concluded, warnings were added to the label of Xeljanz as well as two other oral JAK drugs for arthritis – Eli Lilly's Olumiant (baricitinib) and AbbVie's Rinvoq (upadacitinib ...

Pfizer has claimed its first regulatory approval worldwide for Cibinqo ... Two other JAK inhibitors – Eli Lilly's Olumiant (baricitinib) and AbbVie's Rinvoq (upadacitinib) – have already ...

and JAK (Rinvoq) pathways. These new pathways seem to offer better efficacy and an improved side effect profile over Humira. Further helping offset Humira sales erosion, aesthetic and therapeutic ...

WASHINGTON -- Giant cell arteritis (GCA) can be successfully treated with the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq), allowing corticosteroids to be withdrawn, results of a phase ...

Skyrizi is an interleukin-23 (IL-23)-inhibiting monoclonal antibody while Rinvoq is a small molecule Janus kinase (JAK) inhibitor. The company is also investigating the potential of both biologics ...